Drug Trial Radar · NCT07288554
A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Sep 5, 2025
Primary completion
Dec 31, 2026
Study completion May 30, 2027
Sponsor
- Lead sponsor
- Bambusa TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-Blind, placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Obstructive Pulmonary Disease (COPD).
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
BBT002Drug
BBT002 will be administered
PlaceboDrug
Placebo will be administered
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events following single and multiple administration of BBT002Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in Laboratory assessmentsTime frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in vital sign measurements following dose administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in physical examination following dose administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
- Number of participants with change in 12-lead ECG readingsTime frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical Univesity
Hefei, Anhui, China · Recruiting
The third affiliated hosptial of Guangzhou Medical University
Guangzhou, Guangdong, China · Recruiting
The First Affiliated Hospital of Guangdong Medical University
Guangzhou, Guangdong, China · Recruiting
Jiangmen Central Hospital
Jiangmen, Guangdong, China · Recruiting
Qingyuan People's Hospital
Qingyuan, Guangdong, China · Recruiting
The First People's Hospital of Xinxiang City
Xinxiang, Henan, China · Recruiting
Yichang Central People's Hospital
Yichang, Hubei, China · Recruiting
The Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China · Recruiting
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China · Recruiting
Chengdu fifth People's Hospital
Chengdu, Sichuang, China · Recruiting
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.